Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

  • LAST PRICE
    265.2900
  • TODAY'S CHANGE (%)
    -4.6600 (-1.7262%)
  • Bid / Lots
    252.8900/ 1
  • Ask / Lots
    278.5400/ 1
  • Open / Previous Close
    268.4700 / 269.9500
  • Day Range
    264.2300
    268.8900
  • 52 Week Range
    141.9750
    304.3900
  • Volume
    939,459

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ALNY
Alnylam Pharmaceuticals Inc
34.8B
-101.2x
---
RPRX
Royalty Pharma PLC
16.1B
18.3x
+1.83%
NDOI
Endo Inc
1.9B
0.4x
---
MCKPF
Mallinckrodt PLC
1.6M
0.0x
---
PBH
Prestige Consumer Healthcare Inc
3.7B
18.3x
---
AMRX
Amneal Pharmaceuticals Inc
2.6B
-13.3x
---
As of 2024-11-05

Company Information

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Contact Information

Headquarters
675 W Kendall StCAMBRIDGE, MA, United States 02142-1168
Phone
617-551-8200
Fax
617-551-8101

Executives

Independent Chairman of the Board
Amy Schulman
Chief Executive Officer, Director
Yvonne Greenstreet
Chief Financial Officer, Executive Vice President
Jeffrey Poulton
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Kevin Fitzgerald
Chief Medical Officer, Executive Vice President - Development and Medical Affairs
Pushkal Garg

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$34.8B
Revenue (TTM)
$2.1B
Shares Outstanding
129.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.34
EPS
$-2.62
Book Value
$-1.75
P/E Ratio
-101.2x
Price/Sales (TTM)
16.6
Price/Cash Flow (TTM)
---
Operating Margin
-8.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.